WHO Recommends Against Using Gilead's Remdesivir for COVID-19
The controversy over Gilead Sciences' (NASDAQ: GILD) remdesivir continues.
A month ago, the Food and Drug Administration (FDA) approved the drug, which goes by the trade name Veklury, to treat COVID-19, the disease caused by the novel coronavirus. But now the World Health Organization's panel of international experts has concluded that there's no evidence that the drug helps COVID-19 patients.
The FDA approval was supported by a 1,062-patient study run by the National Institutes of Health that showed patients who were treated with Veklury recovered from COVID-19 in an average of 10 days compared to 15 days for those who were given a placebo.
Source Fool.com
